Nan Fung Trinity HK Ltd. Has $6.08 Million Stock Position in Bicara Therapeutics Inc. $BCAX

Nan Fung Trinity HK Ltd. increased its position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) by 12.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 384,885 shares of the company’s stock after buying an additional 42,000 shares during the period. Nan Fung Trinity HK Ltd. owned 0.70% of Bicara Therapeutics worth $6,077,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Skandinaviska Enskilda Banken AB publ lifted its holdings in Bicara Therapeutics by 160.9% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 99,236 shares of the company’s stock worth $922,000 after purchasing an additional 61,201 shares during the last quarter. Schroder Investment Management Group raised its position in shares of Bicara Therapeutics by 921.0% in the 2nd quarter. Schroder Investment Management Group now owns 425,341 shares of the company’s stock valued at $3,951,000 after buying an additional 383,681 shares in the last quarter. Artisan Partners Limited Partnership bought a new stake in shares of Bicara Therapeutics during the 2nd quarter worth approximately $3,742,000. TD Asset Management Inc boosted its position in shares of Bicara Therapeutics by 71.5% during the 2nd quarter. TD Asset Management Inc now owns 224,538 shares of the company’s stock worth $2,086,000 after acquiring an additional 93,600 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey increased its stake in Bicara Therapeutics by 119.6% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,109 shares of the company’s stock valued at $75,000 after acquiring an additional 4,417 shares during the last quarter.

Bicara Therapeutics Price Performance

Shares of NASDAQ BCAX opened at $16.80 on Friday. The firm has a market cap of $920.34 million, a PE ratio of -7.50 and a beta of -0.79. Bicara Therapeutics Inc. has a 1 year low of $7.80 and a 1 year high of $19.71. The company has a 50 day simple moving average of $17.52 and a 200 day simple moving average of $14.89.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.12). As a group, research analysts anticipate that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

BCAX has been the subject of several recent analyst reports. Wells Fargo & Company upped their target price on Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. BTIG Research restated a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. HC Wainwright reaffirmed a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Wedbush reissued an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. Finally, Citizens Jmp initiated coverage on shares of Bicara Therapeutics in a research report on Thursday. They set a “market perform” rating and a $31.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $28.33.

Insider Transactions at Bicara Therapeutics

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 12,500 shares of the firm’s stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $18.05, for a total value of $225,625.00. Following the completion of the sale, the chief operating officer owned 193,641 shares of the company’s stock, valued at approximately $3,495,220.05. This trade represents a 6.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider David Raben sold 5,500 shares of Bicara Therapeutics stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $18.45, for a total transaction of $101,475.00. Following the transaction, the insider owned 35,497 shares of the company’s stock, valued at $654,919.65. This represents a 13.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 95,922 shares of company stock worth $1,784,142 in the last three months. Insiders own 15.50% of the company’s stock.

Bicara Therapeutics Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.